Viva Biotech Holdings

SEHK:1873 株式レポート

時価総額:HK$1.1b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Viva Biotech Holdings マネジメント

マネジメント 基準チェック /34

Viva Biotech Holdings'の CEO はChen Cheney Maoで、 Jul2018年に任命され、 の在任期間は 5.92年です。 の年間総報酬はCN¥ 2.39Mで、 60.8%給与と39.2%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の15.66%を直接所有しており、その価値はHK$ 187.81M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と5.2年です。

主要情報

Chen Cheney Mao

最高経営責任者

CN¥2.4m

報酬総額

CEO給与比率60.8%
CEO在任期間5.9yrs
CEOの所有権15.7%
経営陣の平均在職期間3.2yrs
取締役会の平均在任期間5.2yrs

経営陣の近況

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19
Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Recent updates

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19
Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 14
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03
Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26
A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19
Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25
These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11
Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14
These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Dec 23
Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Nov 06
Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Jun 13
Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Apr 17
We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13
Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06
Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02
What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21
Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

CEO報酬分析

Viva Biotech Holdings の収益と比較して、Chen Cheney Mao の報酬はどのように変化したか?
日付総報酬給与会社業績
Dec 31 2023CN¥2mCN¥1m

-CN¥116m

Sep 30 2023n/an/a

-CN¥276m

Jun 30 2023n/an/a

-CN¥436m

Mar 31 2023n/an/a

-CN¥482m

Dec 31 2022CN¥3mCN¥1m

-CN¥528m

Sep 30 2022n/an/a

-CN¥209m

Jun 30 2022n/an/a

CN¥111m

Mar 31 2022n/an/a

CN¥199m

Dec 31 2021CN¥2mCN¥1m

CN¥288m

Sep 30 2021n/an/a

CN¥258m

Jun 30 2021n/an/a

CN¥228m

Mar 31 2021n/an/a

-CN¥79m

Dec 31 2020CN¥1mCN¥957k

-CN¥387m

Sep 30 2020n/an/a

-CN¥349m

Jun 30 2020n/an/a

-CN¥311m

Mar 31 2020n/an/a

-CN¥23m

Dec 31 2019CN¥1mCN¥954k

CN¥266m

報酬と市場: Chen Cheneyの 総報酬 ($USD 329.37K ) は、 Hong Kong市場 ($USD 233.86K ) の同規模の企業の平均を上回っています。

報酬と収益: Chen Cheneyの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Chen Cheney Mao (62 yo)

5.9yrs

在職期間

CN¥2,394,000

報酬

Dr. Chen Cheney Mao, Ph D has been Chairman of Viva Biotech Holdings since July 03, 2018 and served as Chief Executive Officer of Viva Biotech Holdings since July 03, 2018 until December 1, 2023. He Founde...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Chen Cheney Mao
Chairman & CEO5.9yrsCN¥2.39m15.66%
CN¥ 177.7m
Ying Wu
Executive VP & Executive Director5.9yrsCN¥2.68m0.80%
CN¥ 9.1m
Delin Ren
Executive Directorless than a yearCN¥3.68m0.69%
CN¥ 7.9m
Zheren Wang
Co-Chief Financial Officerless than a yearデータなしデータなし
Wei Xiong
Co-Chief Financial Officerless than a yearデータなしデータなし
Xueheng Cheng
Chief Technology Officer4.8yrsデータなしデータなし
Zhixiong Ye
Chief Scientific Officer5.9yrsデータなしデータなし
Han Dai
Chief Innovation Officer & Head of Viva BioInnovatorno dataデータなしデータなし
Jianhua Cai
Senior Vice Presidentno dataデータなしデータなし
Jianguo Ma
Senior VP & President of Shanghai Langhua Pharmaceuticalno dataデータなしデータなし
Xianyong Bu
CBO & EVP of Viva Biotech (Shanghai)no dataデータなしデータなし
Rongqiang Liu
Senior Vice President1.6yrsデータなしデータなし

3.2yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: 1873の経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Chen Cheney Mao
Chairman & CEO5.9yrsCN¥2.39m15.66%
CN¥ 177.7m
Ying Wu
Executive VP & Executive Director14.8yrsCN¥2.68m0.80%
CN¥ 9.1m
Delin Ren
Executive Director5.9yrsCN¥3.68m0.69%
CN¥ 7.9m
Haiguang Wang
Independent Non-Executive Director5.2yrsCN¥225.00kデータなし
Lei Fu
Independent Non-Executive Director5.2yrsCN¥225.00kデータなし
Xiangrong Li
Independent Non-Executive Director5.2yrsCN¥225.00kデータなし
Yuting Wu
Non-Executive Director1.6yrsCN¥225.00kデータなし
Hui Wang
Non-Executive Directorless than a yearデータなし3.97%
CN¥ 45.1m

5.2yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: 1873の 取締役会経験豊富 であると考えられます ( 5.2年の平均在任期間)。